Literature DB >> 8993392

PACAP/VIP receptors in pancreatic beta-cells: their roles in insulin secretion.

N Inagaki1, H Kuromi, S Seino.   

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide belonging to the vasoactive intestinal polypeptide (VIP)/glucagon/secretin family. We have isolated a third PACAP receptor subtype, designated PACAPR-3, by molecular cloning. The cDNA encoding PACAPR-3 has been isolated from a mouse insulin-secreting beta-cell line MIN6 cDNA library. Mouse PACAPR-3 is a protein of 437 amino acids that has 50% and 51% identity with rat PACAP type I and type II receptors, respectively. We have expressed PACAPR-3 in mammalian cells and Xenopus oocytes. PACAPR-3 binds to VIP as well as PACAP-38 and -27, with a slightly higher affinity for PACAP-38, and is positively coupled to adenylate cyclase. PACAP-38, -27, and VIP evoked Ca2+ activated-Cl- currents in Xenopus oocytes. RNA blotting studies reveal that PACAPR-3 mRNA is expressed widely in tissues and cell lines, including pancreatic islets, insulin-secreting cell lines (MIN6, HIT-T15, and RINm5F), lung, brain, stomach, colon, and heart. Furthermore, insulin secretion from the MIN6 cells is stimulated significantly by PACAP-38 and VIP. The possible mechanisms of insulin secretion by PACAP and VIP are also discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8993392     DOI: 10.1111/j.1749-6632.1996.tb17472.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  5 in total

1.  Biological pathway-based genome-wide association analysis identified the vasoactive intestinal peptide (VIP) pathway important for obesity.

Authors:  Yong-Jun Liu; Yan-Fang Guo; Li-Shu Zhang; Yu-Fang Pei; Na Yu; Ping Yu; Christopher J Papasian; Hong-Wen Deng
Journal:  Obesity (Silver Spring)       Date:  2010-04-08       Impact factor: 5.002

2.  In vitro mechanism of action on insulin release of S-22068, a new putative antidiabetic compound.

Authors:  L Le Brigand; A Virsolvy; D Manechez; J J Godfroid; B Guardiola-Lemaître; F M Gribble; F M Ashcroft; D Bataille
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

3.  Preclinical evaluation of PAC1 targeting with radiolabeled Maxadilan.

Authors:  Lieke Joosten; Maarten Brom; Martin K H Schäfer; Otto C Boerman; Eberhard Weihe; Martin Gotthardt
Journal:  Sci Rep       Date:  2017-05-11       Impact factor: 4.379

4.  Diabetes relief in mice by glucose-sensing insulin-secreting human α-cells.

Authors:  Kenichiro Furuyama; Simona Chera; Léon van Gurp; Daniel Oropeza; Luiza Ghila; Nicolas Damond; Heidrun Vethe; Joao A Paulo; Antoinette M Joosten; Thierry Berney; Domenico Bosco; Craig Dorrell; Markus Grompe; Helge Ræder; Bart O Roep; Fabrizio Thorel; Pedro L Herrera
Journal:  Nature       Date:  2019-02-13       Impact factor: 49.962

5.  Candidate master microRNA regulator of arsenic-induced pancreatic beta cell impairment revealed by multi-omics analysis.

Authors:  Jenna E Todero; Kieran Koch-Laskowski; Qing Shi; Matt Kanke; Yu-Han Hung; Rowan Beck; Miroslav Styblo; Praveen Sethupathy
Journal:  Arch Toxicol       Date:  2022-03-21       Impact factor: 6.168

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.